UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

Clinical cancer research, 1997-08, Vol.3 (8), p.1277-1288

1997

Volltextzugriff (PDF)

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma : A report of the children's cancer group

Cancer, 1997-07, Vol.80 (2), p.317-333

1997

Volltextzugriff (PDF)

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2)

Clinical cancer research, 1996-12, Vol.2 (12), p.1951-1959

1996

Volltextzugriff (PDF)

Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study

Clinical cancer research, 1996-02, Vol.2 (2), p.319-330

1996

Volltextzugriff (PDF)

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice

Cancer Immunology, Immunotherapy, 1999-08, Vol.48 (5), p.219-229

1999

Volltextzugriff (PDF)

Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins

Clinical and Diagnostic Laboratory Immunology, 1999-03, Vol.6 (2), p.236-242

1999

Volltextzugriff (PDF)

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

JNCI : Journal of the National Cancer Institute, 1988-11, Vol.80 (18), p.1451-1461

1988

Volltextzugriff (PDF)

A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases : A case of fatal central nervous system thrombosis

Cancer, 2000-04, Vol.88 (8), p.1892-1901

2000

Volltextzugriff (PDF)

Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations

Clinical cancer research, 1999-02, Vol.5 (2), p.281-289

1999

Volltextzugriff (PDF)

Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy

Clinical cancer research, 1998-05, Vol.4 (5), p.1287-1296

1998

Volltextzugriff (PDF)

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors

Journal of immunotherapy (1997), 1996-05, Vol.19 (3), p.184-191

1996

Volltextzugriff (PDF)

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer

Cancer research (Chicago, Ill.), 1988-05, Vol.48 (9), p.2561-2567

1988

Volltextzugriff (PDF)

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells

The Journal of immunology (1950), 1986-07, Vol.137 (2), p.502-511

1986

Volltextzugriff (PDF)

Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer

Clinical cancer research, 1995-05, Vol.1 (5), p.481-491

1995

Volltextzugriff (PDF)

Functional Interleukin-2 Receptors Are Expressed on Natural Killer-Like Leukemic Cells From a Dog With Cutaneous Lymphoma

Blood, 1995-07, Vol.86 (2), p.636-645

1995

Volltextzugriff (PDF)

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2

Cancer research (Chicago, Ill.), 1989-09, Vol.49 (17), p.4941-4944

1989

Volltextzugriff (PDF)

Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy

Cancer Immunology, Immunotherapy, 1998-08, Vol.46 (6), p.327-337

1998

Volltextzugriff (PDF)

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma

Journal of immunotherapy (1997), 1996-07, Vol.19 (4), p.278-295

1996

Volltextzugriff (PDF)

Antibody-directed, effector cell-mediated tumor destruction

Hematology/oncology clinics of North America, 2001-08, Vol.15 (4), p.703-721

2001

Volltextzugriff (PDF)

Repetitive weekly cycles of interleukin-2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity

Cancer research (Chicago, Ill.), 1989-12, Vol.49 (23), p.6832-6839

1989

Volltextzugriff (PDF)

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype

Cancer research (Chicago, Ill.), 1990-05, Vol.50 (9), p.2683-2691

1990

Volltextzugriff (PDF)

The appearance of hypodense eosinophils during interleukin-2 treatment

Journal of allergy and clinical immunology, 1990-03, Vol.85 (3), p.557-566

1990

Volltextzugriff (PDF)

Antigen-Specific Recognition of Autologous Leukemia Cells and Allogeneic Class-I MHC Antigens by IL-2-Activated Cytotoxic T Cells From a Patient With Acute T-Cell Leukemia

Blood, 1989-07, Vol.74 (1), p.343-353

1989

Volltextzugriff (PDF)

Specific recognition of human leukemic cells by allogeneic T cell lines

Transplantation, 1989-09, Vol.48 (3), p.486-494

1989

Volltextzugriff (PDF)

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

Cancer Immunology Immunotherapy, 1989-08, Vol.29 (4), p.261-269

1989

Volltextzugriff (PDF)

1 – 25 von 1.383

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.106)
Mit Volltextzugriff
(1.158)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.359)
Japanisch
(135)
Französisch
(14)
Deutsch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(753)
Life Sciences & Biomedicine
(575)
Humans
(408)
Biological And Medical Sciences
(270)
Male
(242)
Female
(192)
Animals
(189)
Medical Sciences
(189)
Physical Sciences
(144)
Adult
(133)
Social Sciences
(120)
Middle Aged
(111)
Technology
(94)
Aged
(91)
Fundamental And Applied Biological Sciences. Psychology
(88)
Oncology
(78)
Pharmacology. Drug Treatments
(78)
Mice
(71)
Rats
(67)
Exact Sciences And Technology
(61)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma : A report of the children's cancer group

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2)

Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice

Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins

Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin

A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases : A case of fatal central nervous system thrombosis

Distinct Clinical and Laboratory Activity of Two Recombinant Interleukin-2 Preparations

Differential quantitative effects of interleukin (IL)-2 and IL-15 on cytotoxic activity and proliferation by lymphocytes from patients receiving in vivo IL-2 therapy

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells

Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer

Functional Interleukin-2 Receptors Are Expressed on Natural Killer-Like Leukemic Cells From a Dog With Cutaneous Lymphoma

Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2

Transcription factor activation in lymphokine activated killer cells and lymphocytes from patients receiving IL-2 immunotherapy

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma

Antibody-directed, effector cell-mediated tumor destruction

Repetitive weekly cycles of interleukin-2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity

Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype

The appearance of hypodense eosinophils during interleukin-2 treatment

Antigen-Specific Recognition of Autologous Leukemia Cells and Allogeneic Class-I MHC Antigens by IL-2-Activated Cytotoxic T Cells From a Patient With Acute T-Cell Leukemia

Specific recognition of human leukemic cells by allogeneic T cell lines

Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation

Suchergebnisse filtern